These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7443441)

  • 1. [Prolonged probucol treatment in patients with cardiovascular diseases (author's transl)].
    Scebat L; Renais J
    Nouv Presse Med; 1980 Oct; 9(40):3008-10. PubMed ID: 7443441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia.
    LeLorier J; DuBreuil-Quidoz S; Lussier-Cacan S; Huang YS; Davignon J
    Arch Intern Med; 1977 Oct; 137(10):1429-34. PubMed ID: 335998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical research on the hypolipidemic action of a probucol preparation].
    Naumova R; Kerekovska M; Goranov I; Balabanski L
    Vutr Boles; 1986; 25(2):73-7. PubMed ID: 3716382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol.
    Cohen L; Morgan J
    J Fam Pract; 1988 Feb; 26(2):145-50. PubMed ID: 3339318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probucol further lowers the serum cholesterol of colestipol-treated patients with hypercholesterolemia.
    Schonfeld G; Witztum J; Basich P
    Artery; 1982; 10(2):99-104. PubMed ID: 7092583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of probucol on skin cholesterol concentrations in patients with type II hyperlipoproteineamia (author's transl)].
    Beaumont JL; Jacotot B; Buxtorf JC; Meliço-Silvestre AA; Beaumont V
    Nouv Presse Med; 1980 Oct; 9(40):2995-3000. PubMed ID: 7443438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term effects of probucol on serum lipid levels.
    McCaughan D
    Arch Intern Med; 1981 Oct; 141(11):1428-32. PubMed ID: 7025778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia].
    Tvorogova MG; Lupanov VP; Nuraliev EIu; Zaĭtseva TM; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(8):17-21. PubMed ID: 9770737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative effects of probucol and placebo on blood cholesterol in patients on long-term treatment (author's transl)].
    Mc Caughan D
    Nouv Presse Med; 1980 Oct; 9(40):3018-20. PubMed ID: 7443444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)].
    Tedeschi RE; Martz BL; Taylor HA; Cerimelle BJ
    Nouv Presse Med; 1980 Oct; 9(40):3021-7. PubMed ID: 7003530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma levels of probucol in man after single and repeated oral doses (author's transl)].
    Heeg JF; Tachizawa H
    Nouv Presse Med; 1980 Oct; 9(40):2990-4. PubMed ID: 7443437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)].
    Rouffy J; Chanu B; Bakir R; Goy-Loepper J; Saya C
    Nouv Presse Med; 1980 Oct; 9(40):3014-7. PubMed ID: 7443443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypolipidemic effects of DH581 during prolonged administration (author's transl)].
    Nash DT
    G Ital Cardiol; 1976; 6(3):550-5. PubMed ID: 1010207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of probucol in treating primary hypercholesterolemia.
    Enjalbert M; Lussier-Cacan S; DuBreuil-Quidoz S; LeLorier J; Davignon J
    Can Med Assoc J; 1980 Oct; 123(8):754-7. PubMed ID: 7448680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of probucol on the cholesterol content of skin in type II hyperlipoproteinemias.
    Beaumont JL; Jacotot B; Buxtorf JC; Silvestre M; Beaumont V
    Artery; 1982; 10(1):71-87. PubMed ID: 7092577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of probucol on plasma cholesterol and triglyceride levels].
    Duarte GM; Lavall M
    Arq Bras Cardiol; 1981 Nov; 37(5):431-7. PubMed ID: 7347193
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacology of probucol. I].
    Donatelli L
    Clin Ter; 1984 Mar; 108(5):367-88. PubMed ID: 6232074
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum cholesterol and triglyceride levels in patients with type II hyperlipoproteinemia treated with probucol].
    Markiewicz M; Rymar B; Horubała-Bielak G; Koziara Z
    Wiad Lek; 1984 Oct; 37(19):1489-93. PubMed ID: 6528586
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical assessment of probucol and its therapeutical effect on hypercholesterolaemia (author's transl)].
    Herdová J; Zapletalová J
    Cas Lek Cesk; 1981 Jul; 120(27):832-5. PubMed ID: 7261004
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
    Fiorini F; Patrone E; Castelluccio A
    Clin Ter; 1994 Sep; 145(9):213-7. PubMed ID: 7813167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.